<div id="readability-page-1"><p>Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has received an average recommendation of &#34;Moderate Buy&#34; from the five analysts that are presently  covering the company, MarketBeat reports. One analyst  has rated the stock with a sell recommendation, three have given a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $10.00.</p><p>Several research analysts have weighed in on the stock. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Metagenomi in a research note on Tuesday, August 19th. Chardan Capital cut their price objective on Metagenomi from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a report on Friday, August 15th. Zacks Research upgraded Metagenomi from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday. Wells Fargo &amp; Company dropped their target price on Metagenomi from $16.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, August 14th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Metagenomi in a report on Wednesday, October 8th.</p><p><b>Check Out Our Latest Analysis on MGX</b></p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC lifted its stake in  Metagenomi by 53.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company's stock worth $32,000 after purchasing an additional 7,458 shares during the period.  Virtu Financial LLC bought a new stake in  Metagenomi in the first quarter valued at $43,000.  Bank of New York Mellon Corp lifted its holdings in shares of  Metagenomi by 39.6% during the first quarter. Bank of New York Mellon Corp now owns 50,387 shares of the company's stock valued at $69,000 after acquiring an additional 14,296 shares during the period.  Bank of America Corp DE grew its holdings in shares of  Metagenomi by 482.9% in the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company's stock worth $76,000 after purchasing an additional 17,491 shares during the last quarter.  Finally, Nuveen LLC acquired a new stake in shares of  Metagenomi during the 1st quarter worth about $86,000. </p><h2>Metagenomi Stock Up 9.8%</h2><p>NASDAQ:MGX opened at $3.35 on Tuesday. The stock has a fifty day simple moving average of $2.22 and a 200 day simple moving average of $1.91. The firm has a market capitalization of $125.73 million, a price-to-earnings ratio of -1.42 and a beta of 0.27. Metagenomi has a 1-year low of $1.23 and a 1-year high of $4.92. </p><p>Metagenomi (NASDAQ:MGX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.14. The company had revenue of $8.51 million during the quarter, compared to analysts' expectations of $7.72 million. Metagenomi had a negative net margin of 257.99% and a negative return on equity of 37.84%.  Equities analysts predict that  Metagenomi will post -2.46 earnings per share for the current year. </p><h2>Metagenomi Company Profile</h2> (Get Free Report)<p>Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Metagenomi</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>Will D-Wave's European Expansion Keep Fueling the Rally?</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable?</li><li>What is a penny stock? A comprehensive guide</li><li>Cash Burn vs. Cautious Capital: Which eVTOL Strategy Will Win</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Metagenomi Right Now?</h2><p>Before you consider Metagenomi, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.</p><p>While Metagenomi currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Metagenomi, Inc. (NASDAQ:MGX) has received a consensus recommendation of "Moderate Buy" from five analysts. The average 1-year price target is $10.00, with one sell, three buy, and one strong buy rating. Recent institutional investments include Vanguard increasing its stake by 53.1%. The stock price rose 9.8% to $3.35, with a market cap of $125.73 million. Metagenomi reported a quarterly EPS of ($0.54), exceeding estimates, and revenue of $8.51 million. Analysts predict a -2.46 EPS for the current year.</p>

Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of "Moderate Buy" by Analysts